Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/155797
Title: The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models
Author: Gómez Miragaya, Jorge
Moran, Sebastian
Calleja Cervantes, Maria E.
Collado-Solé, Alejandro
Paré, Laia
Gómez, Antonio
Serra, Violeta
Dobrolecki, Lacey E.
Lewis, Michael T.
Diaz-Lagares, Angel
Eroles, Pilar
Prat Aparicio, Aleix
Esteller, Manel
González Suárez, Eva
Keywords: Càncer de mama
Pacients
ADN
Metilació
Breast cancer
Patients
DNA
Methylation
Issue Date: 1-Oct-2019
Publisher: American Association for Cancer Research
Abstract: Taxanes are standard therapy in clinical practice for metastatic breast cancer; however, primary or acquired chemoresistance are a common cause of mortality. Breast cancer patient-derived xenografts (PDX) are powerful tools for the study of cancer biology and drug treatment response. Specific DNA methylation patterns have been associated to different breast cancer subtypes but its association with chemoresistance remains unstudied. Aiming to elucidate docetaxel resistance mechanisms, we performed genome-wide DNA methylation in breast cancer PDX models, including luminal and triple-negative breast cancer (TNBC) models sensitive to docetaxel, their matched models after emergence of chemoresistance and residual disease after short-term docetaxel treatment. We found that DNA methylation profiles from breast cancer PDX models maintain the subtype-specific methylation patterns of clinical samples. Two main DNA methylation clusters were found in TNBC PDX and remain stable during the emergence of docetaxel resistance; however, some genes/pathways were differentially methylated according to docetaxel response. A DNA methylation signature of resistance able to segregate TNBC based on chemotherapy response was identified. Transcriptomic profiling of selected sensitive/resistant pairs and integrative analysis with methylation data demonstrated correlation between some differentially methylated and expressed genes in docetaxel-resistant TNBC PDX models. Multiple gene expression changes were found after the emergence of docetaxel resistance in TNBC. DNA methylation and transcriptional changes identified between docetaxel-sensitive and -resistant TNBC PDX models or residual disease may have predictive value for chemotherapy response in TNBC. IMPLICATIONS: Subtype-specific DNA methylation patterns are maintained in breast cancer PDX models. While no global methylation changes were found, we uncovered differentially DNA methylated and expressed genes/pathways associated with the emergence of docetaxel resistance in TNBC.
Note: Versió postprint del document publicat a: https://doi.org/10.1158/1541-7786.MCR-19-0040
It is part of: Molecular Cancer Research, 2019, vol. 17, num. 10, p. 2063-207
URI: http://hdl.handle.net/2445/155797
Related resource: https://doi.org/10.1158/1541-7786.MCR-19-0040
ISSN: 1541-7786
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
695389.pdf6.15 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.